ANPD001 (personalized cell therapy)
Phase 1: first human safety tests
An experimental cell transplant that uses a person's own cells to grow replacement dopamine neurons. Early safety data are encouraging; whether it works is unknown.
- Stage: Phase 1/2a (ASPIRO)
- Type: Disease-modifying
- Developer: Aspen Neuroscience
- Target: Dopamine cell replacement (autologous)
- How it works: A cell therapy that turns a person's own cells into dopamine-producing nerve cells and surgically implants them into the brain to replace those lost to Parkinson's.
- Who it's for: People with moderate-to-advanced Parkinson's.
- Key trials: NCT06344026
- Last reviewed: 2026-08-07
What it is
Like bemdaneprocel, this approach replaces the dopamine-making cells lost in Parkinson's rather than the chemical itself. The difference is that ANPD001 is made from each patient's own cells (autologous), which is intended to avoid the immune-suppressing drugs that donor-cell (allogeneic) transplants require.
Where it stands
The ASPIRO Phase 1/2a trial has begun dosing people with moderate-to-advanced Parkinson's. Early six-month data from the first few patients were reported in 2025 as safe and well tolerated, with preliminary hints of improvement. This is very early work.
What the data shows so far
The first reported data came from just the initial three patients at six months and were designed to assess safety, not to prove benefit. Any reported improvements are from a tiny, uncontrolled group; surgical Parkinson's studies carry a strong placebo effect, so only a larger, sham-controlled trial could show real benefit.
What families should know
Using a patient's own cells is an appealing idea because it may avoid immune-suppression, but this remains experimental, involves brain surgery, and is years from being widely available, if it succeeds. Beware clinics selling 'stem cell cures' for Parkinson's today; those are not the same thing and are not proven.
Caveats
Efficacy is unproven; the early data are from a handful of patients in a safety-focused study. Involves brain surgery. Surgical Parkinson's trials have a large placebo effect, so only a controlled trial can show real benefit. Making cells individually is complex and slow.
Timeline
Most recent first.
- 2025, Six-month data from first three patients reported as safe and well tolerated.
- 2024, ASPIRO Phase 1/2a trial begins dosing.
Sources
Last reviewed: 2026-08-07. Back to the Parkinson's drug pipeline